Natera (NTRA) PE Ratio: History & Chart

Natera, Inc.(NTRA)

Medical - Diagnostics & Research · Austin, TX

$410.35+1.88 (+0.46%)

Delayed quote: Oct 2, 2026, 4:00 PM EDT

About Natera, Inc.

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

Austin, TX

6,138 employees

www.natera.com

Healthcare / Medical - Diagnostics & Research

Sector: Healthcare
Industry: Medical - Diagnostics & Research
CEO: Steven Leonard Chapman

View full financials

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Natera, Inc. (NTRA)	$58.77B	N/A	N/A	N/A	N/A
Cencora, Inc. (COR)vs ›	$60.13B	22.96	32.84	30.14	25.95
Boston Scientific Corporation (BSX)vs ›	$63.32B	17.32	34.53	58.91	69.34
Cardinal Health, Inc. (CAH)vs ›	$53.47B	31.58	31.28	46.17	44.32
Edwards Lifesciences Corporation (EW)vs ›	$49.03B	48.94	40.09	28.82	33.19
Becton, Dickinson and Company (BDX)vs ›	$48.72B	53.25	34.08	34.55	34.25
Agilent Technologies, Inc. (A)vs ›	$47.38B	33.03	29.24	29.94	31.31
Humana Inc. (HUM)vs ›	$46.63B	36.78	27.84	23.34	22.27
Cigna Corporation (CI)vs ›	$71.48B	11.20	12.42	19.03	16.89
Teva Pharmaceutical Industries Limited (TEVA)vs ›	$46.04B	65.88	39.30	39.30	31.35

NAME

MARKET CAP

PE RATIO

TTM

Natera, Inc. (NTRA)

$58.77B

N/A

Cencora, Inc. (COR)vs ›

$60.13B

22.96

32.84

30.14

25.95

Boston Scientific Corporation (BSX)vs ›

$63.32B

17.32

34.53

58.91

69.34

Cardinal Health, Inc. (CAH)vs ›

$53.47B

31.58

31.28

46.17

44.32

Edwards Lifesciences Corporation (EW)vs ›

$49.03B

48.94

40.09

28.82

33.19

Becton, Dickinson and Company (BDX)vs ›

$48.72B

53.25

34.08

34.55

34.25

Agilent Technologies, Inc. (A)vs ›

$47.38B

33.03

29.24

29.94

31.31

Humana Inc. (HUM)vs ›

$46.63B

36.78

27.84

23.34

22.27

Cigna Corporation (CI)vs ›

$71.48B

11.20

12.42

19.03

16.89

Teva Pharmaceutical Industries Limited (TEVA)vs ›

$46.04B

65.88

39.30

31.35

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

PE Ratio: N/A

NTRA PE Ratio Metrics

NTRA Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics